Genasense (oblimersen sodium)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Genasense (oblimersen sodium), covering 2013-01-24 to 2024-05-30. Get the full timeline:
Most recent: Clinical Trial Update: Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia [Phase 3]